Filing Flows › Iovance Biotherapeutics (IOVA) › Q3 2025
Iovance Biotherapeutics (IOVA) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Iovance Biotherapeutics (IOVA) reported revenue of $67.5M for the third quarter 2025 (Q3 2025), +15% from a year earlier and +13% from the quarter before. Operating margin was -140.7%, net loss $91.3M (135.3% of revenue).
Iovance Biotherapeutics, Q3 2025: revenue $67.5M (+15% year over year), operating margin -140.7%, net loss $91.3M, operating cash flow −$78.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $67.5M | +13% | +15% |
| Operating profit | −$94.9M | — | — |
| Net earnings | −$91.3M | — | — |
| Operating cash flow | −$78.7M | — | — |
What changed
Revenue was $67.5M in Q3 2025, up 15% year over year and up 13% from the previous quarter. Amtagvi was the largest line at 85% of revenue. Amtagvi added $15.4M year over year (up 37%), 174% of the total change. PROLEUKIN declined 40%.
Operating costs exceeded revenue by $94.9M, an operating margin of -140.7%. Total costs grew 10% against revenue growth of 15%. The fastest-growing cost line was Other operating costs (+45%). The quarter ended with a net loss of $91.3M, narrower than the previous quarter's $111.7M loss.
Operating cash flow was −$78.7M. Non-cash charges added back $3.2M of depreciation and amortization and $11.9M of share-based compensation. Capital expenditures of $10.8M exceeded it, leaving free cash flow of −$89.5M.
Questions
What was Iovance Biotherapeutics' revenue in the third quarter 2025?
Iovance Biotherapeutics (IOVA) reported revenue of $67.5M for the third quarter 2025 (Q3 2025), +15% from a year earlier and +13% from the quarter before.
Was Iovance Biotherapeutics profitable in the third quarter 2025?
Operating loss was $94.9M (-140.7% of revenue) and net loss $91.3M.